title: Hepatitis B virus infection, hepatitis B vaccine, and hepatitis B immune globulin.
abstract: Hepatitis B virus (HBV) infection is a major health problem in the United States; in 1995, approximately 128,000 cases occurred. Transmission of HBV occurs primarily by blood exchange (eg, by shared needles during injection drug use) and by sexual contact. Persons infected early in life are much more likely to become chronically infected than those infected during adulthood: as many as 90% of infants infected perinatally develop chronic infection and up to 25% will die of HBV-related chronic liver disease as adults. Clinical signs of acute hepatitis occur in about 50% of infected adults but in only 5% of infected preschool-aged children. In the United States, hepatitis B vaccine is currently made by recombinant DNA technology using baker's yeast. Preexposure vaccination results in protective antibody levels in almost all infants and children (> 95%) and healthy adults younger than 40 years of age (> 90%). The most common adverse event following administration of hepatitis B vaccine is pain at the injection site, which occurs in 13% to 29% of adult and 3% to 9% of children. A comprehensive hepatitis B vaccination policy is now recommended that includes (1) routine infant vaccination; (2) catch-up vaccination of 11- to 12-year-olds who were not previously vaccinated; (3) catch-up vaccination of young children at high risk for infection; (4) vaccination of adolescents and adults based on lifestyle or environmental, medical, and occupational situations that place them at risk; and (5) prevention of perinatal HBV infection.
authors.affiliation: Department of Family Medicine and Clinical Epidemiology, University of Pittsburgh School of Medicine, USA.
authors.forename: R K
authors.initials: RK
authors.lastname: Zimmerman
authors.forename: F L
authors.initials: FL
authors.lastname: Ruben
authors.forename: E R
authors.initials: ER
authors.lastname: Ahwesh
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D005194:Family Practice; D006509:Hepatitis B / Q000175:diagnosis / Q000276:immunology / Q000517:prevention & control* / Q000635:transmission; D017325:Hepatitis B Vaccines / Q000009:adverse effects / Q000276:immunology; D006801:Humans; D007114:Immunization; D007116:Immunization, Passive; D007136:Immunoglobulins; D007223:Infant; D014481:United States
chemical_list: D017325:Hepatitis B Vaccines; D007136:Immunoglobulins; C045213:hepatitis B hyperimmune globulin